SIXTY-EIGHTH
ANNUAL MEETING

November 20–24, 2019 | astmh.org | ajt mh.org | @TropMed19 #iamTropMed

GAYLORD NATIONAL RESORT AND CONVENTION CENTER | NATIONAL HARBOR, MARYLAND, USA

ASTMH is an international society committed to equity and global impact through the treatment and prevention of tropical infectious diseases. Our diverse membership comes from more than 115 countries... we are committed to the open exchange of ideas, freedom of thought and expression, and productive scientific debate... open and diverse environment that is built on dignity and mutual respect for all. We oppose discrimination based on personal attributes including but not limited to: ethnicity, color, national origin, age, religion, socioeconomic status, disability, sexual orientation, gender, and gender identity or expression.

ASTMH is an international society committed to equity and global impact through the treatment and prevention of tropical infectious diseases. Our diverse membership comes from more than 115 countries... we are committed to the open exchange of ideas, freedom of thought and expression, and productive scientific debate... open and diverse environment that is built on dignity and mutual respect for all. We oppose discrimination based on personal attributes including but not limited to: ethnicity, color, national origin, age, religion, socioeconomic status, disability, sexual orientation, gender, and gender identity or expression.

Supplement to
The American Journal of Tropical Medicine and Hygiene
eliminated virus infectivity but did not impact E protein expression, antigenicity, virion assembly, or particle budding. We identified variants that showed increased DENV virion budding, up to 5-fold above wild-type, indicating the ability to engineer highly expressed, non-infectious DENV variants for use in vaccine design. To identify uncharacterized DENV cellular receptors we assayed wild-type DENV RVP infectivity in non-permissive cells expressing our membrane proteome array (MPA) of 5,300 unique human membrane proteins. This has identified candidate membrane proteins that enable DENV infectivity. We have identified neutralizing epitopes in DENV pMVE and specific sites that are critical for DENV infectivity, providing new targets and opportunities for vaccine development.

208

INTERCURRENT FLAVIVIRAL VIREMIA IN ILL RETURNED TRAVELERS WITH PLASMODIUM VIVAX MALARIA

Katherine Faith Tan1, Ruwandi Karinawasam2, Rachel Lau3, Filip Ralevski3, Andrea K. Boggild4

1Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada; 2Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada; 3Public Health Ontario, Toronto, ON, Canada

Similar epidemiology and clinical presentations of arboviral infections and malaria coupled with the typically sequential approach to diagnostic testing, where malaria is confirmed or excluded urgently in febrile returned travelers, may mask the true epidemiology of co-infections. Flaviviruses are known to trigger relapsing forms of malaria, including Plasmodium vivax, long after primary malaria infection, and this may delay the diagnosis of malaria. We aim to understand the incidence of intercurrent flaviviral infection in confirmed Plasmodium vivax infection. DNA and RNA from biobanked isolates of P. vivax detected in whole blood at the Public Health Ontario Laboratory between 2006 and 2018 were extracted and screened for intercurrent flaviviral infections using previously validated real-time PCR (qPCR) assays targeting multiple flaviviruses (pan-FLAV) and, specifically, dengue virus types 1-4 (DEN1, DEN2, DEN3, DEN4). Five hundred and two unique isolates of P. vivax were identified, of which 90 have been tested to date. Males accounted for 65.6% (n=59/90) of P. vivax cases, while females accounted for 32.2% (n=29/90), and sex was unassigned in 2.2% (2/90). Median age of P. vivax cases was 33.2 years (range 3.7 years - 85.8 years, IQR 23.4 - 45.9 years). Median parasitemia was 0.2% (range <0.01% - 1.1%). Fifty-nine (65.6%) P. vivax cases had documented travel history exclusively to South Asia, with India as the most common source country (22/90 [16.7%]). Pan-FLAV assay yielded a 1.1% (1/90) positivity rate. Pan-DEN assay will be performed next. Intercurrent flaviviral viremia was noted in at least 1.1%, which may suggest that primary flaviviral infection triggered a relapse of P. vivax. Alternatively, such co-occurrence may suggest primary infection with both organisms known to cause fever in returning travelers. Consideration of flaviviral co-infection should be given to the P. vivax patient with deep thrombocytopenia, lymphopenia, and high-yield arboviral symptomatology such as rash and retro-orbital headache.

209

DETECTION AND SEQUENCING OF ZIKA VIRUS IN NORMOCEPHALIC NEWBORNS WITH CONGENITAL ZIKA INFECTION

Breno L. de Almeida1, Marta Giovanetti1, João V. Oliveira1, Tereza C. Xavier1, Eduardo M. Figueirêdo1, Jaqueline J. Goes1, Luiz C. Alcantara1, Iсадora C. de Siqueira1

1Fundação Oswaldo Cruz-Fiocruz, Salvador, Brazil; 2Maternidade de Referência Prof José Maria de Magalhães Neto, Salvador, Brazil; 3Maternidade de Referência Prof José Maria de Magalhães Neto, Salvador, Brazil

In 2015, Brazil has experienced an unprecedented Zika virus (ZIKV) outbreak and later that year, an unexpected outbreak of newborns with microcephaly occurred in major cities in northeastern Brazil, associated with Congenital Zika Infection (CZI). Most descriptions and publications regarding CZI focus on the clinical presentation of newborns and infants with microcephaly. Scarce information is available concerning CZI without microcephaly. During hospital surveillance for CZI in a reference maternity hospital, we identified 14 normocephalic newborns with confirmed CZI. Eight (57%) of the newborns were female and the mean gestational age at birth was 38.46 ± 1.90 weeks. The mean of head circumference was 38.57 ± 1.40 cm. The transfemoral ultrasonography was performed in 13 (92.9%), and no alterations were observed in any of the cases. All newborns had a positive RT-PCR confirming the diagnosis of CZI, mostly in urine samples (57%). In two of the cases, ZIKV were detected in 2 distinct samples. ZIKV-specific RT-PCR amplification products have been obtained and N5 gene fragments (426-bp) were obtained using Sanger sequencing. The phylogenetic analysis showed that the isolate belongs to the Asian genotype and clusters closely with strong bootstrap support (85%) with sequences isolated in Northeast and Northern regions of Brazil. With this, we infer that CZI could present in a broad spectrum of clinical manifestation, including the asymptomatic presentation at birth. It is necessary careful surveillance to identify cases with few or no symptoms at birth and a close follow-up for early detection of clinical manifestations of CZI and timely intervention.

210

ZIKA VIRUS DETECTION IN PREVIOUSLY UNDIAGNOSABLE SAMPLES: OPTIMIZATION OF A QUANTITATIVE RT-PCR ASSAY FOR SAMPLES OF LOW VIRAL CONCENTRATION

Alejandra García Glassner1, Patricia Barrera2, Amy C. Morrison1, Thomas W. Scott3, Mariana Legua1

1Genomics Laboratory, Pontificia Universidad Católica del Perú, Lima, Peru; 2Asociación Benéfica Prisma, Lima, Peru; 3Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, CA, United States; 4Department of Entomology and Nematology, University of California, Davis, CA, United States

The Zika virus (ZIKV) outbreak of 2015 affected many countries in Latin America and highlighted a pressing need for sensitive molecular diagnostics to detect the presence of ZIKV in various sample types. At the time, only two RT-qPCR assays, developed by Faye et al. and Lanciotti et al., were available to diagnose human ZIKV infections. These assays used primer sets that target separate regions of the ZIKV genome with enough specificity to serve as diagnostic tools that could differentiate ZIKV from other related arboviruses, such as dengue and yellow fever. However, their sensitivity was low, resulting in false-negative diagnosis of many ZIKV cases, particularly when ZIKV was present at low levels (CT values around 30 or higher). We developed an improved RT-qPCR protocol that uses optimized primer sets and cycling conditions to detect the presence of ZIKV at levels previously considered undiagnosable (CT values up to 38). The parameters optimized include primer length, GC content and annealing temperature. We also created a positive control plasmid that includes both the N5S and envelope regions of the genome, allowing for side-by-side comparisons of the amplification efficiency of old and new assays. Using this control plasmid, we estimated the limit of detection of our new assay at 31 copies of the viral genome. We used our assay to test a number of samples suspected of being false-negatives and found that about 10% of those re-tested were positive for ZIKV. Our results indicate that the improved ZIKV assay can help address the issue of false-negatives during ZIKV diagnosis and will be a useful tool for those interested in a fast, rapid, and sensitive diagnostic for ZIKV, particularly in samples of low viral concentration encountered during clinical evaluation or research.